Format

Send to

Choose Destination
Am J Clin Oncol. 2014 Oct;37(5):473-9. doi: 10.1097/COC.0b013e31827e4e7b.

Angiosarcoma outcomes and prognostic factors: a 25-year single institution experience.

Author information

1
Departments of *Pathology †Human Oncology §Medicine ∥Dermatology, University of Wisconsin, School of Medicine and Public Health, Madison, WI ‡Moses Cone Regional Cancer Center, Greensboro, NC.

Abstract

OBJECTIVE:

Angiosarcoma is an aggressive malignancy with endothelial differentiation and notoriously poor prognosis despite aggressive therapy. Limited data are available to guide management decisions. To address this limitation, we present a large retrospective analysis of angiosarcoma patients treated at a single institution over a 25-year period.

METHODS:

To identify factors that impact angiosarcoma outcomes, we reviewed demographic, tumor, and treatment characteristics of angiosarcoma patients evaluated at the University of Wisconsin Hospital between 1987 and 2012.

RESULTS:

The cohort included 81 patients diagnosed at ages 19 to 90 years (median, 67 y). Fifty-five (68%) patients presented with localized disease, whereas 26 (32%) presented with metastases. The primary sites were visceral/deep soft tissue (42%), head and neck/cutaneous (37%), breast (16%), and limbs in the setting of Stewart-Treves (5%). The 5-year overall survival was 40% with a median of 16 months. By univariate analysis, significant adverse predictors of survival included metastases at presentation, visceral/deep soft tissue tumor location, tumor size > 5 cm, tumor necrosis, and the absence of surgical excision. A trend toward prolonged survival was observed with radiation therapy and for chemotherapy in patients with metastases. Age, sex, and prior radiation showed no correlation with survival.

CONCLUSIONS:

Our large single institution series confirms the poor prognosis of angiosarcoma, supports a central role for surgical excision in management, and highlights the need for novel therapies particularly in patients who present with metastatic disease.

PMID:
23428947
PMCID:
PMC3664266
DOI:
10.1097/COC.0b013e31827e4e7b
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Wolters Kluwer Icon for PubMed Central
Loading ...
Support Center